NuVasive Competitors

Abbott Laboratories (NYSE:ABT) and NuVasive (NASDAQ:NUVA) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, risk, profitability, valuation and dividends.

Risk & Volatility

Abbott Laboratories has a beta of 0.84, indicating that its share price is 16% less volatile than the S&P 500. Comparatively, NuVasive has a beta of 1.38, indicating that its share price is 38% more volatile than the S&P 500.

Insider and Institutional Ownership

63.9% of Abbott Laboratories shares are held by institutional investors. 1.7% of Abbott Laboratories shares are held by company insiders. Comparatively, 0.9% of NuVasive shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Abbott Laboratories and NuVasive's revenue, earnings per share (EPS) and valuation.

Abbott Laboratories has higher revenue and earnings than NuVasive. NuVasive is trading at a lower price-to-earnings ratio than Abbott Laboratories, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Abbott Laboratories and NuVasive's net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of recent recommendations and price targets for Abbott Laboratories and NuVasive, as provided by MarketBeat.com.

Abbott Laboratories presently has a consensus target price of $115.3750, suggesting a potential upside of 6.93%. NuVasive has a consensus target price of $66.9375, suggesting a potential upside of 37.84%. Given NuVasive's higher possible upside, analysts plainly believe NuVasive is more favorable than Abbott Laboratories.

Summary

Abbott Laboratories beats NuVasive on 12 of the 14 factors compared between the two stocks.

Medtronic (NYSE:MDT) and NuVasive (NASDAQ:NUVA) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, risk, profitability, valuation and dividends.

Risk & Volatility

Medtronic has a beta of 0.64, indicating that its share price is 36% less volatile than the S&P 500. Comparatively, NuVasive has a beta of 1.38, indicating that its share price is 38% more volatile than the S&P 500.

Insider and Institutional Ownership

68.9% of Medtronic shares are held by institutional investors. 0.5% of Medtronic shares are held by company insiders. Comparatively, 0.9% of NuVasive shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Medtronic and NuVasive's revenue, earnings per share (EPS) and valuation.

Medtronic has higher revenue and earnings than NuVasive. NuVasive is trading at a lower price-to-earnings ratio than Medtronic, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Medtronic and NuVasive's net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of recent recommendations and price targets for Medtronic and NuVasive, as provided by MarketBeat.com.

Medtronic presently has a consensus target price of $122.00, suggesting a potential upside of 7.16%. NuVasive has a consensus target price of $66.9375, suggesting a potential upside of 37.84%. Given NuVasive's higher possible upside, analysts plainly believe NuVasive is more favorable than Medtronic.

Summary

Medtronic beats NuVasive on 12 of the 15 factors compared between the two stocks.

Intuitive Surgical (NASDAQ:ISRG) and NuVasive (NASDAQ:NUVA) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, risk, profitability, valuation and dividends.

Risk & Volatility

Intuitive Surgical has a beta of 0.97, indicating that its share price is 3% less volatile than the S&P 500. Comparatively, NuVasive has a beta of 1.38, indicating that its share price is 38% more volatile than the S&P 500.

Insider and Institutional Ownership

75.1% of Intuitive Surgical shares are held by institutional investors. 1.6% of Intuitive Surgical shares are held by company insiders. Comparatively, 0.9% of NuVasive shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Intuitive Surgical and NuVasive's revenue, earnings per share (EPS) and valuation.

Intuitive Surgical has higher revenue and earnings than NuVasive. NuVasive is trading at a lower price-to-earnings ratio than Intuitive Surgical, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Intuitive Surgical and NuVasive's net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of recent recommendations and price targets for Intuitive Surgical and NuVasive, as provided by MarketBeat.com.

Intuitive Surgical presently has a consensus target price of $718.2778, suggesting a potential downside of 7.95%. NuVasive has a consensus target price of $66.9375, suggesting a potential upside of 37.84%. Given NuVasive's higher possible upside, analysts plainly believe NuVasive is more favorable than Intuitive Surgical.

Summary

Intuitive Surgical beats NuVasive on 12 of the 14 factors compared between the two stocks.

Stryker (NYSE:SYK) and NuVasive (NASDAQ:NUVA) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, risk, profitability, valuation and dividends.

Profitability

This table compares Stryker and NuVasive's net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of recent recommendations and price targets for Stryker and NuVasive, as provided by MarketBeat.com.

Stryker presently has a consensus target price of $221.44, suggesting a potential downside of 7.58%. NuVasive has a consensus target price of $66.9375, suggesting a potential upside of 37.84%. Given NuVasive's higher possible upside, analysts plainly believe NuVasive is more favorable than Stryker.

Insider and Institutional Ownership

71.0% of Stryker shares are held by institutional investors. 6.8% of Stryker shares are held by company insiders. Comparatively, 0.9% of NuVasive shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Stryker and NuVasive's revenue, earnings per share (EPS) and valuation.

Stryker has higher revenue and earnings than NuVasive. NuVasive is trading at a lower price-to-earnings ratio than Stryker, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Stryker has a beta of 0.78, indicating that its share price is 22% less volatile than the S&P 500. Comparatively, NuVasive has a beta of 1.38, indicating that its share price is 38% more volatile than the S&P 500.

Summary

Stryker beats NuVasive on 13 of the 15 factors compared between the two stocks.

NuVasive (NASDAQ:NUVA) and Becton, Dickinson and (NYSE:BDX) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, valuation, earnings, profitability and analyst recommendations.

Profitability

This table compares NuVasive and Becton, Dickinson and's net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of recent ratings and target prices for NuVasive and Becton, Dickinson and, as reported by MarketBeat.

NuVasive presently has a consensus target price of $66.9375, suggesting a potential upside of 37.84%. Becton, Dickinson and has a consensus target price of $280.2857, suggesting a potential upside of 15.46%. Given NuVasive's higher possible upside, analysts clearly believe NuVasive is more favorable than Becton, Dickinson and.

Insider & Institutional Ownership

74.4% of Becton, Dickinson and shares are held by institutional investors. 0.9% of NuVasive shares are held by company insiders. Comparatively, 0.1% of Becton, Dickinson and shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares NuVasive and Becton, Dickinson and's revenue, earnings per share and valuation.

Becton, Dickinson and has higher revenue and earnings than NuVasive. NuVasive is trading at a lower price-to-earnings ratio than Becton, Dickinson and, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

NuVasive has a beta of 1.38, indicating that its stock price is 38% more volatile than the S&P 500. Comparatively, Becton, Dickinson and has a beta of 0.77, indicating that its stock price is 23% less volatile than the S&P 500.

Summary

Becton, Dickinson and beats NuVasive on 11 of the 14 factors compared between the two stocks.

NuVasive (NASDAQ:NUVA) and Edwards Lifesciences (NYSE:EW) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, valuation, earnings, profitability and analyst recommendations.

Profitability

This table compares NuVasive and Edwards Lifesciences' net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of recent ratings and target prices for NuVasive and Edwards Lifesciences, as reported by MarketBeat.

NuVasive presently has a consensus target price of $66.9375, suggesting a potential upside of 37.84%. Edwards Lifesciences has a consensus target price of $87.7222, suggesting a potential upside of 2.29%. Given NuVasive's higher possible upside, analysts clearly believe NuVasive is more favorable than Edwards Lifesciences.

Insider & Institutional Ownership

73.8% of Edwards Lifesciences shares are held by institutional investors. 0.9% of NuVasive shares are held by company insiders. Comparatively, 1.5% of Edwards Lifesciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares NuVasive and Edwards Lifesciences' revenue, earnings per share and valuation.

Edwards Lifesciences has higher revenue and earnings than NuVasive. NuVasive is trading at a lower price-to-earnings ratio than Edwards Lifesciences, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

NuVasive has a beta of 1.38, indicating that its stock price is 38% more volatile than the S&P 500. Comparatively, Edwards Lifesciences has a beta of 0.92, indicating that its stock price is 8% less volatile than the S&P 500.

Summary

Edwards Lifesciences beats NuVasive on 11 of the 14 factors compared between the two stocks.